Introduction — Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney disease (CKD) affecting most of the patients in end stage renal disease. Materials and Methods — This prospective case control study was conducted on 50 adult patients of CKD, having individual parathyroid hormone (iPTH) levels >300 pg/ml. These patients were divided into two groups: Group I (n=25) received calcitriol in dosage of 0.5 µg/day. Group II (n=25) received cinacalcet in dosage of 30 mg/day and calcitriol 0.5 µg/day. The study was carried out for 6 month duration. Results — The mean basal value of iPTH decreased to 246.40±219.99 pg/ml at the end of the study from basal value of 482.80±229.86 in group II. There was a 43% decrease in serum iPTH values in group II as opposed to the 14% decrease in group I (P<0.05). Serum Ca×P decreased by 9% in group I and by 13% in group II and there was statistically significant difference at the end of 3rd month as well as at the end of study in cinacalcet group. Conclusion — Cinacalcet is unique in its ability to simultaneously lower PTH, calcium, phosphorus and Ca×P in patients with SHPT and thus could become an important component in treatment of CKD patients.
H.K. Aggarwal, Deepak Jain, Vipin Kaverappa, Sumin Kaushik, Sachin Yadav Role of cinacalcet in the treatment of secondary hyperparathyroidism in chronic kidney disease // Russian Open Medical Journal, Vol. 2, Issue 3, 2013, pp. 309-0